International Assets Investment Management LLC Invests $7.02 Million in GSK plc (NYSE:GSK)

International Assets Investment Management LLC purchased a new position in GSK plc (NYSE:GSK) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 189,520 shares of the pharmaceutical company’s stock, valued at approximately $7,024,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. KCS Wealth Advisory lifted its holdings in GSK by 1.5% in the 3rd quarter. KCS Wealth Advisory now owns 21,391 shares of the pharmaceutical company’s stock worth $775,000 after purchasing an additional 314 shares during the last quarter. Caprock Group LLC boosted its holdings in shares of GSK by 2.8% during the 4th quarter. Caprock Group LLC now owns 11,513 shares of the pharmaceutical company’s stock worth $430,000 after buying an additional 317 shares during the period. Horizon Bancorp Inc. IN grew its stake in GSK by 8.9% in the 4th quarter. Horizon Bancorp Inc. IN now owns 3,961 shares of the pharmaceutical company’s stock valued at $147,000 after buying an additional 323 shares during the last quarter. Simmons Bank raised its holdings in GSK by 0.3% in the 3rd quarter. Simmons Bank now owns 134,584 shares of the pharmaceutical company’s stock worth $4,879,000 after acquiring an additional 364 shares during the period. Finally, AdvisorNet Financial Inc lifted its position in GSK by 1.9% during the 4th quarter. AdvisorNet Financial Inc now owns 20,729 shares of the pharmaceutical company’s stock worth $768,000 after acquiring an additional 377 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Performance

Shares of NYSE:GSK opened at $44.15 on Wednesday. GSK plc has a twelve month low of $33.33 and a twelve month high of $44.33. The business has a fifty day moving average of $41.93 and a 200-day moving average of $39.30. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.58 and a current ratio of 0.87. The firm has a market cap of $91.50 billion, a PE ratio of 16.00, a price-to-earnings-growth ratio of 1.85 and a beta of 0.65.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be paid a $0.3762 dividend. This is a boost from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 annualized dividend and a dividend yield of 3.41%. The ex-dividend date of this dividend is Thursday, May 16th. GSK’s dividend payout ratio (DPR) is 57.61%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GSK. Morgan Stanley initiated coverage on GSK in a research note on Tuesday, January 23rd. They issued an “equal weight” rating for the company. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Finally, Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK presently has a consensus rating of “Moderate Buy”.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.